Novartis Catches Flu Fever: Second Bid Nets Chiron

Novartis' first priority upon the completion of its acquisition of Chiron will be to resolve the flu vaccine maker's outstanding manufacturing issues, Novartis Head of Pharma Development Jörg Reinhardt said during an analyst call announcing the deal Oct. 31